Lee Shinwon, Lee Jeong Eun, Lee Soon Ok, Lee Sun Hee
Department of Internal Medicine, Pusan National University School of Medicine and Medical Research Institute, Pusan National University Hospital, Busan, Korea.
Infect Chemother. 2024 Sep;56(3):386-394. doi: 10.3947/ic.2024.0074.
Limited information is available on the clinical course and treatment outcomes of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection in Korea.
A retrospective case series was conducted of patients with HIV-HCV coinfection who received interferon (IFN)-based or direct-acting antiviral (DAA) treatment for HCV at a tertiary care hospital between 2000 and 2023. Early virological response (EVR) was defined as a 2-log reduction in HCV RNA levels or undetectable HCV RNA levels at treatment week 12. A sustained virologic response (SVR) was defined as undetectable HCV RNA at 12 weeks after treatment completion.
Of the 33 patients with HIV-HCV coinfection, 19 received anti-HCV treatment, of whom 12 received IFN-based treatment and 10 received DAA treatment. The median age at the time of anti-HCV treatment was 49 years (interquartile range, 42-57 years) and 15 patients (79%) were male. Of the 12 patients who received IFN-based anti-HCV treatment, 10 showed EVR and 8 achieved SVR. However, 2 patients who achieved SVR experienced recurrence of HCV infection during follow-up; therefore, the overall success rate of IFN-based treatment was 50% (6/12). All 10 patients (including 3 in whom IFN-based treatment failed) who received DAA treatment (5 with previous anti-HCV treatment and 5 treatment-naïve), achieved SVR and did not experience recurrence of HCV infection during follow-up; therefore, the overall success rate of DAA treatment was 100%.
In Korean patients with HIV-HCV coinfection, treatment outcomes were better with DAA treatment than with IFN-based treatment.
关于韩国人类免疫缺陷病毒（HIV）和丙型肝炎病毒（HCV）合并感染的临床病程和治疗结果的信息有限。
对2000年至2023年期间在一家三级护理医院接受基于干扰素（IFN）或直接作用抗病毒药物（DAA）治疗HCV的HIV-HCV合并感染患者进行回顾性病例系列研究。早期病毒学应答（EVR）定义为治疗第12周时HCV RNA水平降低2个对数或HCV RNA水平检测不到。持续病毒学应答（SVR）定义为治疗完成后12周时HCV RNA检测不到。
在33例HIV-HCV合并感染患者中，19例接受了抗HCV治疗，其中12例接受基于IFN的治疗，10例接受DAA治疗。抗HCV治疗时的中位年龄为49岁（四分位间距，42 - 57岁），15例患者（79%）为男性。在12例接受基于IFN的抗HCV治疗的患者中，10例显示出EVR，8例实现了SVR。然而，2例实现SVR的患者在随访期间出现了HCV感染复发；因此，基于IFN治疗的总体成功率为50%（6/12）。所有10例接受DAA治疗的患者（包括3例基于IFN治疗失败的患者）（5例既往接受过抗HCV治疗，5例初治患者）均实现了SVR，且在随访期间未出现HCV感染复发；因此，DAA治疗的总体成功率为100%。
在韩国HIV-HCV合并感染患者中，DAA治疗的效果优于基于IFN的治疗。
